Valeo Financial Advisors LLC Purchases New Stake in Outset Medical, Inc. (NASDAQ:OM)

Valeo Financial Advisors LLC purchased a new stake in shares of Outset Medical, Inc. (NASDAQ:OM) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 21,653 shares of the company’s stock, valued at approximately $117,000.

Several other institutional investors also recently added to or reduced their stakes in OM. US Bancorp DE boosted its position in Outset Medical by 286.7% during the first quarter. US Bancorp DE now owns 2,711 shares of the company’s stock worth $123,000 after purchasing an additional 2,010 shares during the period. AlphaCrest Capital Management LLC bought a new position in Outset Medical during the first quarter worth about $278,000. MetLife Investment Management LLC boosted its position in Outset Medical by 53.4% during the first quarter. MetLife Investment Management LLC now owns 26,064 shares of the company’s stock worth $1,183,000 after purchasing an additional 9,070 shares during the period. Rhumbline Advisers boosted its position in Outset Medical by 4.2% during the first quarter. Rhumbline Advisers now owns 49,144 shares of the company’s stock worth $2,231,000 after purchasing an additional 2,000 shares during the period. Finally, Lord Abbett & CO. LLC boosted its position in Outset Medical by 1.8% during the first quarter. Lord Abbett & CO. LLC now owns 222,923 shares of the company’s stock worth $10,121,000 after purchasing an additional 4,042 shares during the period.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. BTIG Research assumed coverage on shares of Outset Medical in a research report on Monday, April 8th. They set a “buy” rating and a $6.00 target price for the company. CL King upgraded shares of Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Friday, April 5th. Finally, Royal Bank of Canada downgraded shares of Outset Medical from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $14.00 to $6.00 in a report on Friday, January 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Outset Medical has an average rating of “Hold” and a consensus target price of $5.42.

Outset Medical Stock Up 2.0 %

Shares of Outset Medical stock opened at $2.08 on Wednesday. Outset Medical, Inc. has a 12-month low of $1.92 and a 12-month high of $24.13. The company has a debt-to-equity ratio of 1.06, a current ratio of 5.26 and a quick ratio of 4.37. The company’s 50-day moving average price is $2.70 and its 200-day moving average price is $4.22.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). The firm had revenue of $30.51 million during the quarter, compared to analysts’ expectations of $30.40 million. Outset Medical had a negative return on equity of 102.50% and a negative net margin of 132.54%. As a group, research analysts expect that Outset Medical, Inc. will post -2.28 earnings per share for the current year.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.